GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (MEX:RARE) » Definitions » Cyclically Adjusted PB Ratio

Ultragenyx Pharmaceutical (MEX:RARE) Cyclically Adjusted PB Ratio : 2.98 (As of Jun. 03, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio?

As of today (2025-06-03), Ultragenyx Pharmaceutical's current share price is MXN1150.56. Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was MXN386.70. Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio for today is 2.98.

The historical rank and industry rank for Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio or its related term are showing as below:

MEX:RARE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.66   Med: 3.57   Max: 5.59
Current: 2.8

During the past years, Ultragenyx Pharmaceutical's highest Cyclically Adjusted PB Ratio was 5.59. The lowest was 2.66. And the median was 3.57.

MEX:RARE's Cyclically Adjusted PB Ratio is ranked worse than
66.67% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs MEX:RARE: 2.80

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted book value per share data for the three months ended in Mar. 2025 was MXN31.426. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN386.70 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.79 3.87 3.42

Ultragenyx Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.75 3.29 4.48 3.42 2.97

Competitive Comparison of Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio falls into.


;
;

Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1150.56/386.70
=2.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Ultragenyx Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=31.426/134.9266*134.9266
=31.426

Current CPI (Mar. 2025) = 134.9266.

Ultragenyx Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201506 138.876 100.684 186.108
201509 251.047 100.392 337.408
201512 234.867 99.792 317.557
201603 216.245 100.470 290.406
201606 210.244 101.688 278.966
201609 220.085 101.861 291.528
201612 236.953 101.863 313.866
201703 217.575 102.862 285.398
201706 182.964 103.349 238.867
201709 156.142 104.136 202.310
201712 170.508 104.011 221.189
201803 264.716 105.290 339.229
201806 276.013 106.317 350.288
201809 245.263 106.507 310.708
201812 235.070 105.998 299.225
201903 300.167 107.251 377.625
201906 273.081 108.070 340.946
201909 248.618 108.329 309.659
201912 213.181 108.420 265.299
202003 240.099 108.902 297.477
202006 265.760 108.767 329.677
202009 241.989 109.815 297.325
202012 343.657 109.897 421.927
202103 319.648 111.754 385.927
202106 285.576 114.631 336.137
202109 282.484 115.734 329.329
202112 272.917 117.630 313.049
202203 227.196 121.301 252.717
202206 194.850 125.017 210.295
202209 134.568 125.227 144.992
202212 97.899 125.222 105.486
202303 56.244 127.348 59.591
202306 30.953 128.729 32.443
202309 7.654 129.860 7.953
202312 56.793 129.419 59.210
202403 28.015 131.776 28.685
202406 85.982 132.554 87.521
202409 73.985 133.029 75.040
202412 57.571 133.157 58.336
202503 31.426 134.927 31.426

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ultragenyx Pharmaceutical  (MEX:RARE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.